Bruce Katz, MD, Medical advisory board of Bioform.
Rhoda Narins, MD ,Medical board, consultant, and/or investigator for Q-Med, Artes, Bioform, Johnson & Johnson, Ortho-Neutrogena, Colbar, Merz, Medicis, Contura, Mentor, Stiefel, Allergan, Sanofi Aventis Dermik, and Genzyme.
Ellen Marmur, MD, Medical education faculty for Bioform, Sanofi Aventis, and Allergan.
Joel Schlessinger, MD ,Researcher, advisory board, and/or consultant for 3M Pharma, Abbot Pharma, Allergan, Amgen, Barrier Therapeutics, Bioten, Centocor, Clay-Park Labs, Collagenix, Connetics, Dermik, Dow, ESC Medical, Fujisawa, Galderma, Genentech, Glaxo Pharma, Glenmark Pharma, Healthpoint, Immunex, Ipsen, Kythera, Medicis, Mentor, Merz, Novartis, Novum, Nucryst, Ortho Pharma, Penederm Pharma, Perrigo, Pfizer, QLT USA, Regeneratio Pharma AG, Sandox, Shering Plough, Stiefel Labs, UCB/Vitae, Artes, Glaxo, Health and Wellness Council of America, MJD Communications, Obagi, , and Vaseline Petroleum Jelly (National spokesperson 2000-2001). Stockholder of Allergan, Excel Cosmeceuticals, Medicus, Mentor, Obagi, and TKL Graceway.
Pitocin is administered under a physician's supervision. The initial dose of Pitocin should be -1 mU/min (equal to 3-6 mL of the dilute oxytocin solution per hour). At 30-60 minute intervals the dose should be gradually increased in increments of 1-2 mU/min until the desired contraction pattern has been established. Pitocin may interact with drugs used in anesthesia , prochlorperazine injection, or warfarin. Tell your doctor all medications you use. Pitocin should be used during pregnancy only if prescribed. There are no known indications for use of this medication in the first 3 months of pregnancy other than in relation to spontaneous or induced abortion . Consult your doctor before breastfeeding.
The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism , peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.